Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
CARDIZEM (diltiazem hydrochloride) is a calcium channel blocker indicated for hypertension and angina pectoris. It reduces blood pressure and myocardial oxygen demand by inhibiting calcium influx into vascular and cardiac muscle cells. The oral tablet formulation has been a cornerstone therapy in cardiovascular disease management since 1982.
LOE-approaching status signals transition from growth-focused teams toward lifecycle management and generic defense strategies; expect organizational restructuring and potential team consolidation.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CARDIZEM offers experience in mature product management, generic competition defense, and managed care negotiation—skills highly valuable in pharma. However, limited pipeline activity and approaching LOE mean career growth is constrained; positions are best suited for professionals seeking stability and tactical commercial expertise rather than transformational innovation roles.
Worked on CARDIZEM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo